ShanghaiApril 28, 2026 /PRNewswire/ — Patent Foramen Ovale (PFO) is a common congenital cardiac anatomical variation in adults. Data shows that this anatomical abnormality is prevalent in approximately 25% of the healthy population. Most individuals with PFO do not exhibit typical clinical symptoms, but the underlying pathological risks persist long-term, predisposing them to paradoxical embolism mechanisms, which can lead to secondary neurological complications such as refractory migraines, cryptogenic stroke, and minor brain injuries. Currently, standardized guidelines for PFO diagnosis and treatment have been issued both domestically and internationally. However, numerous academic challenges remain unresolved in areas such as clinical practice, etiological differentiation, imaging assessment, and stratified intervention.
I. Research Highlight: First Domestic Focus on FLAIR Imaging Features in Middle-Aged Health Screening Populations
Recently, a research team led by Dean Huang Lianjun and Director Yang Chengwei at Shanghai Delta Cardiovascular Hospital has achieved groundbreaking progress in the study of brain damage imaging related to Patent Foramen Ovale.
This study is the first in China to focus on a middle-aged and young healthy health screening population. It systematically and deeply investigated brain damage associated with PFO using the characteristic imaging method of cranial magnetic resonance FLAIR (Fluid Attenuated Inversion Recovery) sequences.
The research findings suggest that abnormal high FLAIR signals on brain MRI detected during health screenings in middle-aged and young individuals should be given full attention. Further clarifying whether the subject has PFO is a key step in identifying the cause, as there is a close correlation between the two. This discovery provides a novel imaging perspective for precise PFO diagnosis and individualized intervention.
The research paper, with Shi Ziyu from the Department of Imaging and Interventional Therapy at Shanghai Delta Hospital as the first author, was officially published in the Journal of Cardiovascular and Pulmonary Diseases, Issue 9, 2024. Following publication, the team continued prospective clinical follow-ups, expanding the study sample and refining data comparisons over nearly two years, further validating the clinical reliability and applicability of the study’s conclusions.
II. Clinical Challenge: What Are the Imaging Manifestations of PFO-Related Brain Damage?
Current clinical diagnosis and treatment still face several core issues: What are the characteristic cranial MRI imaging findings of PFO-mediated paradoxical embolism? For asymptomatic middle-aged and young individuals incidentally diagnosed with PFO during health screenings, how can standardized cranial imaging examinations be used, in conjunction with medical history such as migraines and orthostatic hypotension, to objectively assess disease risk levels and develop stratified intervention strategies? Can specific MRI sequences improve the detection efficiency and assessment accuracy of covert brain injuries?
To address these common clinical challenges, the team led by Huang Lianjun and Yang Chengwei, leveraging extensive clinical case data, conducted an in-depth analysis of characteristic abnormal signals on cranial FLAIR sequences in health screening populations. They systematically summarized the imaging signs and distribution patterns of intracranial lesions caused by PFO-derived paradoxical embolism. Additionally, they clarified the clinical application value of cranial FLAIR characteristic imaging indicators in risk assessment and disease grading for asymptomatic middle-aged and young PFO patients, filling theoretical gaps and clinical shortcomings in this research field.
III. Clinical Significance: Providing a New Pathway for Cryptogenic Stroke Screening in Middle-Aged and Young Populations
As an authoritative research team in the field of cardiovascular imaging and interventional therapy in China, the academic leader, Professor Huang Lianjun, has been deeply involved in cardiovascular imaging and interventional treatment for over 40 years. He possesses profound academic expertise and extensive clinical experience in the imaging assessment and interventional treatment of congenital heart disease, aortic diseases, and peripheral vascular diseases.
Statistics indicate that 40% to 50% of patients with cryptogenic stroke have concurrent Patent Foramen Ovale, and this comorbidity has a higher incidence in middle-aged and young populations without traditional cardiovascular risk factors. Additionally, chronic conditions such as refractory migraines and difficult-to-treat orthostatic hypotension are closely related to PFO anatomical abnormalities and hemodynamic changes.
This research outcome, grounded in real-world clinical practice, reveals a strong association between characteristic FLAIR signals on brain MRI in middle-aged and young health screening populations and PFO. It provides important evidence-based medical support for clinical risk assessment and the development of individualized intervention plans for this group, ensuring scientific diagnosis and treatment are grounded in evidence. At the same time, it helps minimize the risk of overtreatment or missed diagnosis and treatment, offering a clearer and more feasible pathway for early screening and prevention of cryptogenic stroke in middle-aged and young populations.
This team’s research closely aligns with practical clinical diagnostic and treatment needs, clarifying the association between abnormal cranial FLAIR signals and Patent Foramen Ovale in middle-aged and young health screening populations. It provides solid evidence-based medical support for early risk screening, prognosis assessment, and individualized treatment planning for this group. This can guide clinicians in accurately identifying high-risk cases and implementing timely standardized interventions, while reasonably avoiding unnecessary medical procedures, reducing the risk of missed diagnosis and treatment, and continuously improving the full-cycle standardized diagnostic and treatment system for PFO.